https://www.selleckchem.com/pr....oducts/rottlerin.htm
Finally, we discuss the prospect of fusion genes as therapeutic targets in gynecologic tumors.Abiraterone, a novel androgen synthesis inhibitor, has been approved for castration-resistant prostate cancer (CRPC) treatment. However, most patients eventually acquire resistance to this agent, and the underlying mechanisms related to this resistance remain largely unelucidated. Lysine acetyltransferase 2 A (KAT2A) has been reported to enhance transcriptional activity for certain histone or non-histone proteins through the acetylation and p
Curtir
Comentario
Compartilhar
